Equities

Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc

Actions
  • Price (USD)0.3564
  • Today's Change-2.51 / -87.55%
  • Shares traded3.24m
  • 1 Year change-88.47%
  • Beta--
Data delayed at least 20 minutes, as of Nov 13 2024 19:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments140202130
Total Receivables, Net01.692.98
Total Inventory------
Prepaid expenses5.457.393.24
Other current assets, total------
Total current assets145211137
Property, plant & equipment, net192527
Goodwill, net------
Intangibles, net------
Long term investments--013
Note receivable - long term------
Other long term assets1.595.352.94
Total assets168244183
LIABILITIES
Accounts payable126.413.69
Accrued expenses182017
Notes payable/short-term debt000
Current portion long-term debt/capital leases6.670.070.29
Other current liabilities, total04.3310
Total current liabilities373132
Total long term debt354140
Total debt414141
Deferred income tax------
Minority interest------
Other liabilities, total804526
Total liabilities15211798
SHAREHOLDERS EQUITY
Common stock0.030.020.06
Additional paid-in capital739686549
Retained earnings (accumulated deficit)(723)(558)(464)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total00.10(0.08)
Total equity1712885
Total liabilities & shareholders' equity168244183
Total common shares outstanding26206.20
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.